Detail akcie Medpace Holdings online

Business Summary: Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Medpace Holdings Inc revenues increased 20% to $2.53B. Net income applicable to common stockholders increased 12% to $451.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Interest Expense/Income - Net decrease of 49% to $12.8M (income), Selling, general and administrative - B increase of 6% to $174.9M (expense).